AVAX Technologies Inc (AVXT)

[katter]

http://www.americanbankingnews.com/2016/06/27/sarepta-therapeutics-inc-srpt-stock-rating-reaffirmed-by-robert-w-baird/

Sarepta Therapeutics Inc (NASDAQ:SRPT)‘s stock had its “outperform” rating reissued by equities researchers at Robert W. Baird in a research note issued on Monday. They presently have a $23.00 target price on the stock. Robert W. Baird’s price objective would suggest a potential upside of 24.19% from the company’s current price.

A number of large investors recently made changes to their positions in SRPT. Schwab Charles Investment Management Inc. increased its stake in shares of Sarepta Therapeutics by 14.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 147,945 shares of the company’s stock worth $5,708,000 after buying an additional 18,323 shares in the last quarter. American International Group Inc. increased its stake in shares of Sarepta Therapeutics by 9.0% in the fourth quarter. American International Group Inc. now owns 31,421 shares of the company’s stock worth $1,212,000 after buying an additional 2,598 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock worth $32,354,000 after buying an additional 689,831 shares in the last quarter. Morgan Stanley increased its stake in shares of Sarepta Therapeutics by 22.4% in the fourth quarter. Morgan Stanley now owns 133,785 shares of the company’s stock worth $5,162,000 after buying an additional 24,477 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock worth $2,319,000 after buying an additional 358 shares in the last quarter.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 9.131% during trading on Monday, reaching $16.829. 1,446,298 shares of the company’s stock traded hands. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $41.97. The stock’s market cap is $770.33 million. The company’s 50 day moving average is $18.45 and its 200-day moving average is $20.35.

Search Results
Baird 'Incrementally Positive' on Sarepta (SRPT) Following 'Shocking ...
www.streetinsider.com/Analyst.../Baird...on+Sarepta+(SRPT).../11532815.html
Apr 22, 2016 - Baird analyst Brian Skorney is incrementally positive on the FDA's move to include voting questions on Sarepta Therapeutic (NASDAQ: SRPT) ...
Robert W. Baird Reaffirms Buy Rating for Sarepta Therapeutics Inc ...
www.americanbankingnews.com/.../robert-w-baird-reaffirms-buy-rating-for-sarepta-t...
Jun 11, 2016 - Sarepta Therapeutics logo Sarepta Therapeutics Inc (NASDAQ:SRPT)'s stock had its “buy” rating reaffirmed by analysts at Robert W. Baird in a ...
Sarepta Therapeutics Inc (SRPT) Receives Outperform Rating from ...
www.americanbankingnews.com/.../sarepta-therapeutics-inc-srpt-receives-outperform...
May 26, 2016 - Sarepta Therapeutics Inc (NASDAQ:SRPT)'s stock had its “outperform” rating restated by Robert W. Baird in a research note issued to investors ...
Sarepta Therapeutics Inc (SRPT) Given Buy Rating at Robert W. Baird ...
www.com-unik.info/sarepta-therapeutics-inc-srpt-given-buy-rating-at-robert-w-baird/
Jun 13, 2016 - Sarepta Therapeutics Inc - Receive News & Ratings Daily. ... Sarepta Therapeutics Inc (NASDAQ:SRPT)‘s stock had its “buy” rating restated by stock analysts at Robert W. Baird in a report released on Friday. ... Mutual of America Capital Management LLC raised its position in shares of